Home » Stocks » MYGN

Myriad Genetics, Inc. (MYGN)

Stock Price: $18.66 USD 1.12 (6.39%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $18.75 +0.09 (0.48%) Dec 1, 4:28 PM

Stock Price Chart

Key Info

Market Cap 1.40B
Revenue (ttm) 597.50M
Net Income (ttm) -194.10M
Shares Out 75.21M
EPS (ttm) -2.61
PE Ratio n/a
Forward PE 370.37
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $18.66
Previous Close $17.54
Change ($) 1.12
Change (%) 6.39%
Day's Open 17.76
Day's Range 17.46 - 18.87
Day's Volume 674,794
52-Week Range 9.78 - 29.53

More Stats

Market Cap 1.40B
Enterprise Value 1.53B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 75.21M
Float n/a
EPS (basic) -2.61
EPS (diluted) -2.61
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.91M
Short Ratio 15.89
Short % of Float n/a
Beta 1.46
PE Ratio n/a
Forward PE 370.37
P/FCF Ratio n/a
PS Ratio 2.35
PB Ratio 1.51
Revenue 597.50M
Operating Income -255.00M
Net Income -194.10M
Free Cash Flow -24.70M
Net Cash -131.30M
Net Cash / Share -1.75
Gross Margin 75.73%
Operating Margin -42.68%
Profit Margin -32.50%
FCF Margin -4.13%
ROA -6.40%
ROE -19.58%
ROIC -42.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 1
Overweight 0
Hold 5
Underweight 1
Sell 3

Analyst Consensus: Hold

Price Target

$17.12*
(-8.25% downside)
Low
8.00
Current: $18.66
High
30.00
Target: 17.12
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue639851744729741723778613496402
Revenue Growth-24.97%14.44%2.06%-1.59%2.41%-7.08%26.91%23.63%23.36%-
Gross Profit453650567558583576669534431355
Operating Income-2358.7060.7043.20153134274228180158
Net Income-2004.6013317.4011780.20176147112101
Shares Outstanding74.3073.5069.4068.3070.0071.3075.7080.9084.6189.79
Earnings Per Share-2.690.061.850.251.601.082.251.771.301.10
EPS Growth--96.76%640%-84.38%48.15%-52%27.12%36.15%18.18%-
Operating Cash Flow60.7083.70116106166141190174142131
Capital Expenditures-10.20-8.60-8.40-6.10-5.00-23.90-14.30-11.40-9.41-3.79
Free Cash Flow50.5075.10108100161117176163132127
Cash & Equivalents218137181151159145186372341346
Total Debt2952349.3099.10------
Net Cash / Debt-77.00-96.6017151.60159145186372341346
Assets1,4051,5631,1751,209881766824804691611
Liabilities48647420944113210410575.2354.9844.04
Book Value9181,089966768748662719729636567
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Myriad Genetics, Inc.
Country United States
Employees 2,700
CEO Paul J. Diaz

Stock Information

Ticker Symbol MYGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: MYGN
IPO Date October 5, 1995

Description

Myriad Genetics, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.